Uveitis in patients with axial spondyloarthritis or psoriatic arthritis: a post hoc analysis from placebo-controlled phase III studies with secukinumab.

BACKGROUND

The incidence rate of uveitis in secukinumab-treated patients with axial spondyloarthritis (axSpA) was previously reported.

OBJECTIVE

To evaluate the incidence rate of uveitis in patients with axSpA and psoriatic arthritis (PsA) treated with secukinumab or placebo during placebo-controlled phase III studies.

DESIGN

This was a post hoc analysis from 11 phase III studies.

METHODS

Pooled data from axSpA (MEASURE 1-5 and PREVENT studies) and PsA (FUTURE 1-5 studies) were analyzed.

RESULTS

In the axSpA cohort ( = 1980), the incidence rate for uveitis was 1.29 per 100 patient-years in the secukinumab 150 mg and 1.72 per 100 patient-years in the placebo arm. In the PsA cohort ( = 2453), the incidence rate for uveitis was 0.71 per 100 patient-years in the secukinumab 300 mg arm; no events were reported in the placebo arm.

CONCLUSION

During the placebo-controlled phase, a numerically lower incidence of uveitis was observed in secukinumab-treated axSpA patients. In PsA patients, the incidence was low in secukinumab-treated patients, while uveitis was not reported in the placebo group.